Urogen's Chief Medical Officer Insider Trade: 400K Sale Insights
A high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Identify which index funds yield the strongest after-tax returns in 2024. Learn how tax considerations impact fund performance and retirement strategy.
28,085 articlesA high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
A high-stakes clash between Anthropic and the Pentagon nears a Friday deadline, drawing attention from markets and pe...
GRNY beats COWZ by 11 points this year, signaling a tilt toward AI, electrification, and energy themes. Oil prices an...
Investors confront a tough choice: buy Nvidia for big gains or rely on NVDY's weekly income stream, which comes with ...
Two tech powerhouses sit at the AI crossroads. This article breaks down the nvidia stock micron stock dynamic, what h...
A china tech fund opens a biotech position, signaling a broader shift toward life sciences within tech-driven portfol...
As the AI arms race accelerates, payroll budgets are tightening. Major firms are delaying raises and halting 401(k) m...
A new decade of grid investment is underway, backed by policy and utility plans. Three ETFs are poised to capture the...
A federal judge blocked the Trump administration from labeling Anthropic a supply chain risk, calling the move a poss...
Turning Point Brands stock has surged, even as a prominent fund dumped millions in TPB shares. This article breaks do...
The Federal Reserve’s newest inflation outlook suggests a higher-for-longer rate path, but investors are cautiously u...
Two years after NVIDIA's stock split, investors again wonder if the AI titan can reach $1,000. This article breaks do...